For discovering tumor angiogenesis, and for pioneering work in the development of
antiangiogenic therapies for cancer.
Not exact matches
HER2 signaling modulates the equilibrium between pro-and
antiangiogenic factors via distinct pathways: implications
for HER2 - targeted antibody
therapy.
In summary, our novel data suggest that ER - α — positive and negative breast cancer subtypes respond differently to hypoxic exposure and as a consequence, anti-HIF-1α or
antiangiogenic therapies will not be suitable
for both subtypes.
As ER - α is considered a reliable biomarker in immunohistochemical analyses and is already used to guide endocrine treatment it would be a suitable treatment predictive marker
for antiangiogenic therapies.
Dr. Jain's nominators note that, in sum, his work has provided ``... unprecedented molecular, cellular, anatomical and functional insights into the vascular pathophysiology of tumors,
for proposing the seminal hypothesis that
antiangiogenic therapy can «normalize» the aberrant vasculature and microenvironment of tumors and thereby improve both delivery and efficacy of treatment of solid tumors.»